Clinical data | |
---|---|
Trade names | Vesicare, Vesicare LS |
Other names | YM905 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605019 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 90% |
Protein binding | 98% |
Metabolism | CYP3A4 |
Metabolites | Glucuronide, N-oxide, others |
Elimination half-life | 45 to 68 hours |
Excretion | Kidney (69.2%) and fecal (22.5%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H26N2O2 |
Molar mass | 362.473 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Solifenacin, sold as the brand name Vesicare[a] among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO).[1][2] It may help with incontinence, urinary frequency, and urinary urgency.[3]
Benefits appear similar to other medications in the class.[4] It is taken by mouth.[1]
Common side effects include dry mouth, constipation, and urinary tract infection.[1][2] Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis.[1][3][2] It is unclear if use is safe during pregnancy.[1] It is of the antimuscarinic class and works by decreasing bladder contractions.[1]
Solifenacin was approved for medical use in the United States in 2004.[1][2][5] In 2022, it was the 210th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[6][7]
Cite error: There are <ref group=lower-alpha>
tags or {{efn}}
templates on this page, but the references will not show without a {{reflist|group=lower-alpha}}
template or {{notelist}}
template (see the help page).
FDA approval
was invoked but never defined (see the help page).